Pain Management in Cancer Patients Using a Mobile Application (ePAL)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02069743|
Recruitment Status : Active, not recruiting
First Posted : February 24, 2014
Last Update Posted : December 12, 2018
|Condition or disease||Intervention/treatment||Phase|
|Cancer||Other: ePAL Mobile Application||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||110 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Supportive Care|
|Official Title:||Pain Management in Cancer Patients Using a Mobile Application|
|Study Start Date :||February 2014|
|Actual Primary Completion Date :||August 2018|
|Estimated Study Completion Date :||December 2018|
The intervention group will use the study's mobile application during the 8-week study.
Other: ePAL Mobile Application
A mobile application designed to help cancer patients better self-manage cancer pain.
Other Name: ePAL
No Intervention: Control
The control group will not use the study's mobile application during the study.
- Pain intensity [ Time Frame: 8-weeks ]The primary aim is to assess the effect of a tailored, multi-dimensional mobile-based intervention on the intensity of cancer pain in cancer patients with moderate to severe pain.
- Quality of Life [ Time Frame: 4 & 8-weeks ]
- Hospital utilization for pain crisis [ Time Frame: 4 and 8-weeks ]
- In-patient and out-patient hospital visits
- Urgent non-scheduled clinic visits for pain crisis
- Daily opioid consumption [ Time Frame: 4 & 8-weeks ]Measured by oral morphine equivalent daily dose
- Perceived barriers to cancer pain management [ Time Frame: 4 & 8-weeks ]BQ-II
- Knowledge of pain management [ Time Frame: 4 & 8-weeks ]PPQ-K
- Engagement [ Time Frame: 4 & 8-weeks ]Pattern of patient engagement with the study's mobile application
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02069743
|United States, Massachusetts|
|The Massachusetts General Hospital|
|Boston, Massachusetts, United States, 02114|
|United States, Minnesota|
|Rochester, Minnesota, United States, 55905|
|Principal Investigator:||Kamal Jethwani, MD, MPH||Massachusetts General Hospital|